3 Reasons Pfizer and BioNTech Will Have Coronavirus Vaccine Data Before Moderna
Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) started the phase 3 clinical trial for their coronavirus vaccine BNT162b2 around the same time as Moderna (NASDAQ: MRNA) started its phase 3 study for mRNA-1273.
But all signs point to Pfizer and BioNTech generating faster efficacy data than Moderna. Here's why:
Pfizer and BioNTech give the booster shot for their vaccine 21 days after the initial dose, while Moderna's protocol calls for doctors to wait 28 days before giving the second dose. Since the efficacy measurements don't start until after the second dose is administered, the difference produces a week advantage for Pfizer and BioNTech.
Source Fool.com
